Immune-mediated Necrotizing Myopathy
📧 Sign up to get email alerts when something new happens for Immune-mediated Necrotizing Myopathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-24Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. [Phase 2, Phase 3]
A Phase 2/3 trial evaluating the efficacy and safety of Efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy has comp…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy [Phase 2, Phase 3]
An open-label Phase 2/3 trial to evaluate the safety and efficacy of CABA-201 in active idiopathic inflammatory myopathy and related juvenil…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy [Phase 3]
A Phase 3 trial evaluating the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic …
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy [Phase 2]
A Phase 2 clinical trial evaluating Ublituximab for autoantibody-positive immune-mediated necrotizing myopathy is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) [Phase 1]
Phase 1b long-term extension trial of RAY121 in multiple immunological diseases is currently enrolling by invitation, expanding early-phase …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS other · 2026-04-02Clinical Trial Update: Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) [Phase 1]
Chugai Pharmaceutical’s RAY121 is being studied in a Phase 1b trial (RAINBOW) across several immunological diseases, and the study is curren…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Add-on Intravenous Immunoglobulins in Early Myositis [Phase 2, Phase 3]
A Phase 2/Phase 3 add-on intravenous immunoglobulin study for early inflammatory myopathies (myositis) is active but not currently recruitin…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
The MIHRA PRISMS clinical study for myositis is currently recruiting, sponsored by the Myositis International Health & Research Collaborativ…
-
CLINICAL_TRIALS research · 2025-07-25Clinical Trial Update: A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy [Phase 1]
Phase 1 clinical trial investigating C-CAR168 for autoimmune diseases refractory to standard therapy is currently recruiting, covering SLE, …
-
CLINICAL_TRIALS other · 2025-07-23Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial is evaluating the efficacy and safety of subcutaneous Efgartigimod PH20 (efgartigimod alfa) in adults with …
-
CLINICAL_TRIALS trial_result · 2022-05-16Clinical Trial Update: Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy [Phase 2]
Phase 2 trial of Zilucoplan in immune-mediated necrotizing myopathy was terminated with posted results in 2022.